Characterization of the canine urinary proteome

Brandt, Laura E.; Ehrhart, E. J.; Scherman, Hataichanok; Olver, Christine S.; Bohn, Andrea; Prenni, Jessica E.

doi:10.1111/vcp.12147

Cited by 29 publications

(23 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a distinct trend away from using the historically popular retro‐orbital sinus/plexus as evolving animal welfare standards continue to encourage the use of other collection routes; a single laboratory indicated that they collect from the retro‐orbital plexus in rats. It has also been reported that CP endpoints are often impacted by the phlebotomy site, highlighting the importance of maintaining consistency within a given study and the need for site‐specific historic control ranges . In mice, routine terminal blood collections were mostly sampled from the vena cava and abdominal aorta (56%), or by cardiac puncture (31%) at necropsy.…”

Section: Phlebotomy Volumes Sites and Methods Of Collectionmentioning

confidence: 99%

“…This approach is commonly employed to generate large quantities of calibration material for use in quality control testing. Sample pooling has also been utilized for mechanistic investigations such as expanded immunotoxicity testing (when primary indicators of immunotoxicity are positive) or broad characterization of the urinary proteome across multiple canine breeds …”

Section: Sample Poolingmentioning

confidence: 99%

“…Sample pooling has also been utilized for mechanistic investigations such as expanded immunotoxicity testing (when primary indicators of immunotoxicity are positive) or broad characterization of the urinary proteome across multiple canine breeds. 12 However in toxicity studies, analysis of samples pooled from individual animals in the same dose group is not recommended. The FDA Redbook 2000 explicitly states that for toxicity studies, "blood samples should be analyzed individually, and not pooled".…”

Section: Sample Poolingmentioning

confidence: 99%

“…It has also been reported that CP endpoints are often impacted by the phlebotomy site, highlighting the importance of maintaining consistency within a given study and the need for site-specific historic control ranges. 12 In mice, routine terminal blood collections were mostly sampled from the vena cava and abdominal aorta (56%), or by cardiac puncture (31%) at necropsy. Interim and survival bleeds of lower volumes (%≤ 250 lL) were obtained by a variety of methods and sites including the tail (38%), jugular (15%), facial (23%), and sublingual veins (15%).…”

Section: Rodent Terminal Collections By Needle and Syringe Or Cathetermentioning

confidence: 99%

See 3 more Smart Citations

Reducing blood volume requirements for clinical pathology testing in toxicologic studies—points to consider

Poitout-Belissent

Aulbach

Tripathi

et al. 2016

Veterinary Clinical Pathol

View full text Add to dashboard Cite

In preclinical safety assessment, blood volume requirements for various endpoints pose a major challenge. The goal of this working group was to review current practices for clinical pathology (CP) testing in preclinical toxicologic studies, and to discuss advantages and disadvantages of methods for reducing blood volume requirements. An industry-wide survey was conducted to gather information on CP instrumentation and blood collection practices for hematology, clinical biochemistry, and coagulation evaluation in laboratory animals involved in preclinical studies. Based on the survey results and collective experience of the authors, the working group proposes the following "points to consider" for CP testing: (1) For most commercial analyzers, 0.5 mL and 0.8 mL of whole blood are sufficient for hematology and biochemistry evaluation, respectively. (2) Small analyzers with low volume requirements and low throughput have limited utility in preclinical studies. (3) Sample pooling or dilution is inappropriate for many CP methods. (4) Appropriate collection sites should be determined based on blood volume requirements and technical expertise. (5) Microsampling does not provide sufficient volume given current analyzer and quality assurance requirements. (6) Study design considerations include: the use of older/larger animals (rodents), collection of CP samples before toxicokinetic samples, use of separate subsets of mice for hematology and clinical biochemistry testing, use of a priority list for clinical biochemistry, and when possible, eliminating coagulation testing.

show abstract

Section: Phlebotomy Volumes Sites and Methods Of Collectionmentioning

confidence: 99%

Section: Sample Poolingmentioning

confidence: 99%

Section: Sample Poolingmentioning

confidence: 99%

Section: Rodent Terminal Collections By Needle and Syringe Or Cathetermentioning

confidence: 99%

See 2 more Smart Citations

Reducing blood volume requirements for clinical pathology testing in toxicologic studies—points to consider

Poitout-Belissent

Aulbach

Tripathi

et al. 2016

Veterinary Clinical Pathol

View full text Add to dashboard Cite

show abstract

“…In veterinary medicine proteomics were performed in such conditions as canine lymphoma [10] and heartworm disease [11] while canine DCM has not yet been studied using proteomics. In addition, although proteomics were performed in several canine body fluids such as cerebrospinal fluid [12] , urine [13] , bronchoalveolar lavage fluid [14] and follicular fluid [15] , no data have yet been presented on ascitic fluid in dogs with DCM. In the present study, we hypothesized that many of the serum proteomes with low abundance and low molecular weight may have roles in the development of DCM in dogs.…”

Section: Introductionmentioning

confidence: 99%

Dilate Kardiyomiyopatili Köpeklerde Serum ve Asites Sıvısı Proteomlarının Araştırılması

Kocatürk¹,

Baykal²,

Turkseven³

et al. 2015

Kafkas Univ Vet Fak Derg

View full text Add to dashboard Cite

The aim of the study was to investigate serum global proteomes in dogs with overt dilated cardiomyopathy (DCM) and to evaluate protein expression in serum with that in ascitic fluid. Eight healthy dogs (control group) and 8 dogs with DCM were included in the study. DCM was diagnosed based on echocardiographic evidence including increased left ventricular dimension at diastole and systole, increased E point to septal separation, and decreased fractional shortening. Serum and ascitic fluid samples were analyzed for proteomes using a label-free LC-MS/MS method. Proteome analyses revealed significantly different expressions of eight proteins in all samples. Expressions in serum of apolipoprotein (Apo) A1, Ig heavy chain V, superoxide dismutase and plasminogen were higher (P<0.001), while expressions of clusterin, hemoglobin subunit ß, Apo-CII, and β2 glycoprotein I (ß2GPI) were lower (P<0.001) in dogs with DCM than in control dogs. In addition, Apo-A1, clusterin, hemoglobin subunit ß, Ig heavy chain V, plasminogen and ß2GPI were down-regulated whereas Apo-CII and superoxide dismutase were up-regulated in ascitic fluid compared with serum in dogs with DCM. Data obtained in the present study suggest that serum and/or ascitic fluid proteomes may explain some of the pathophysiological mechanisms involved in the progression of DCM. Keywords: Dilated cardiomyopathy, DCM, Congestive heart failure, Proteomics, Dog Dilate Kardiyomiyopatili Köpeklerde Serum ve Asites Sıvısı Proteomlarının Araştırılması ÖzetÇalışmamızın amacı ileri düzeyde dilate kardiyomiyopati (DCM) tanısı konulan köpeklerde serum global proteomların araştırılması ve aynı hastaların asites sıvısı proteomları ile ilişkilerinin değerlendirilmesidir. Sekiz sağlıklı (kontrol grubu) ve 8 DCM'li köpek çalışmaya dahil edildi. DCM tanımlaması ekokardiografik olarak sistol ve diyastolde artmış sol ventriküler çap, artmış E point to septal separasyon değeri ve azalmış fraksiyonel kasılma verileri temelinde yapıldı. Serum ve asites sıvı örnekleri label-free LC-MS/MS metoduna göre analiz edilmiştir. Proteom analizi ile tüm örneklerde toplam sekiz adet proteom ekspresyonu belirlendi. DCM'li köpeklerde kontrol grubuna göre serum apolipoprotein (Apo) A1, Ig heavy chain V, superoksit dizmutaz ve plazminojen ekspresyonlarında artış (P<0.001), klasterin, hemoglobin subunit ß, Apo-CII, ve β2 glikoprotein I (ß2GPI) ekspresyonlarında ise azalma (p<0.001) belirlendi. Buna ek olarak; asites sıvısı serum örnekleri ile karşılaştırıldığında Apo-A1, klasterin, hemoglobin subunit ß, Ig heavy chain V, plazminojen ve ß2GPI azalırken, Apo-CII ve superoksit dizmutaz artış gösterdi. Çalışmada elde edilen bu verilerin; serum ve/veya asites sıvısı proteomlarının DCM gelişiminde rolü alan bazı patofizyolojik mekanizmaların açıklanmasına katkı verebileceği kanısındayız.

show abstract

Canine Kidney Safety Protein Biomarkers

Sonee¹

2016

Drug Discovery Toxicology

View full text Add to dashboard Cite

Characterization of the canine urinary proteome

Abstract: The results of this study illustrate the potential of the dog as an animal model for human disease states and provide the framework for future studies of canine renal diseases.

Cited by 29 publications

References 39 publications

Reducing blood volume requirements for clinical pathology testing in toxicologic studies—points to consider

Reducing blood volume requirements for clinical pathology testing in toxicologic studies—points to consider

Dilate Kardiyomiyopatili Köpeklerde Serum ve Asites Sıvısı Proteomlarının Araştırılması

Canine Kidney Safety Protein Biomarkers

Contact Info

Product

Resources

About